Develops immunotherapies for cancer and autoimmune diseases.
Jun 2026Revenue $24.0M/yrExpenses $168M/yr
No trendCash runway over 10 years from Jun 2026
Figures by year
When will Janux Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $24.0M and expenses $168M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $10.0M | $168M | −$158M |
| Dec 2024 | $10.6M | $109M | −$98.8M |
| Dec 2023 | $8.08M | $81.1M | −$73.0M |
| Dec 2022 | $8.61M | $75.7M | −$67.1M |
| Dec 2021 | $3.64M | $36.6M | −$32.9M |
| Dec 2020 | $0.00 | $4.84M | −$4.84M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.